ClinicalTrials.gg
CompletedNCT03101189Updated Jul 10, 2018

A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects

A Phase 1 interventional study of ACT-541468 and placebo in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Netherlands. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-10.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Study summary

So far, ACT-541468 has been studied mainly in Caucasian subjects. The present study will bridge results obtained in Caucasian subjects to those in Japanese subjects.

02

Conditions studied

  • Healthy Subjects

Keywords

  • safety
  • Japanese
  • pharmacokinetics
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Signed form;
  • Healthy male and female subjects aged between 20 and 50 years (inclusive) at screening;
  • Negative serum pregnancy tests at screening and negative urine pregnancy test at Day 1 for women of and agreement to use a reliable method of for at least 90 days after last study drug intake;
  • (BMI) of 18.0 to 26.0 kg/m2 (inclusive) at screening;
  • Healthy on the basis of physical examination, cardiovascular assessments and laboratory tests;
  • Caucasian or Japanese ethnicity.

Japanese subjects only:

  • must be of native Japanese descent (all parents/grandparents of Japanese descent);
  • must not have been away from Japan for more than 10 years (at screening visit);
  • lifestyle should not have changed significantly since relocation from Japan.

Key Exclusion Criteria:

  • Any to the study treatments;
  • History or clinical evidence of any disease or medical / surgical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the absorption, distribution, metabolism or excretion of the study treatments;
  • History of narcolepsy or cataplexy or modified Swiss narcolepsy scale total score \< 0;
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    ACT-541468 (25 mg)

    8 Japanese and 8 Caucasian subjects will receive 25 mg (1 capsule) of ACT-541468 once daily for 5 days

    Drug: ACT-541468

  • Experimental
    ACT-541468 (50 mg)

    8 Japanese and 8 Caucasian subjects will receive 50 mg (2 capsules) of ACT-541468 once daily for 5 days

    Drug: ACT-541468

  • Placebo comparator
    Placebo

    2 Japanese / 2 Caucasian subjects will receive 1 placebo capsule to match subjects in the ACT-541468 (25 mg) group and 2 other Japanese / 2 Caucasian subjects will receive 2 placebo capsules to match subjects in the ACT-541468 (50 mg) group

    Drug: placebo

Interventions

  • Capsule

  • Drugplacebo

    Matching placebo capsule

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of ACT-541468

    The geometric mean Cmax values will be calculated based on pharmacokinetic (PK) blood sampling

    Time frame: From Day1 pre-dose to 48 hours after the last dose on Day 5

  2. Area under the plasma concentration-time curves during a dosing interval [AUC(0-24)] of ACT-541468

    The geometric mean AUC(0-24) values will be calculated based on PK blood sampling

    Time frame: From Day1 pre-dose to 48 hours after the last dose on Day 5

Secondary outcomes

  1. Time to reach Cmax (tmax) of ACT-541468

    The median tmax values will be calculated based on PK blood sampling

    Time frame: From Day1 pre-dose to 48 hours after the last dose on Day 5

  2. Terminal half-life [t(1/2)] of ACT-541468

    The geometric mean t(1/2) values will be calculated based on PK blood sampling

    Time frame: From Day1 pre-dose to 48 hours after the last dose on Day 5

  3. Area under the plasma concentration-time curves from time 0 to 8 h [AUC(0-8)]

    The geometric mean AUC(0-8) values will be calculated based on PK blood sampling

    Time frame: From Day1 pre-dose to 48 hours after the last dose on Day 5

  4. Incidence of treatment-emergent adverse events

    The percentage of subjects with treatment-emergent adverse events will be reported

    Time frame: Up to Day 7 (end of study)

  5. Incidence of adverse events leading to premature discontinuation of study treatment

    The number of subjects who prematurely discontinued the study treatment due to an adverse event will be reported

    Time frame: Up to Day 5

  6. Incidence of any clinical relevant findings in ECG variables

    The number of subjects with any treatment-emergent electrocardiogram (ECG) abnormalities will be reported

    Time frame: Up to Day 7 (end of study)

07

Study locations

1 site
  • Centre for Human Drug Research
    Leiden, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Apr 2017, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2017
First posted
Apr 5, 2017
StartActual
Mar 15, 2017
Primary completionActual
Apr 24, 2017
CompletionActual
Apr 26, 2017
Last update
Jul 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03101189
Responsible party
Sponsor
First posted
Apr 5, 2017
Start date
Mar 15, 2017
Primary completion
Apr 24, 2017
Completion
Apr 26, 2017
Last update
Jul 10, 2018

Study contacts

Clemens Muehlan
study director · Actelion

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion